



INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

A Silent Mutation: The Escalating Crisis Of Antibiotic Resistance And The Call For Global Intervention

Ishal Chhipa

Undergraduate Researcher

Department of Biology

Seton Hall University, New Jersey, USA

Abstract: Antimicrobial/antibiotic resistance is no longer a future concern — it is an ongoing and accelerating threat that threatens to erode the foundation of modern medicine. This paper explores the biological mechanisms that facilitate bacterial resistance, ranging from spontaneous mutation to horizontal gene transfer, and the global misuse of antibiotics in clinical, agricultural, and hospital settings. Using existing global, health-related datasets alongside my own clinical experiences in the emergency department at Hackensack Meridian, I detail how the consequences of resistance impact treatment complexes, lengthen recovery time, and increase the potential risk of harm to patients. Two original figures display the global burden of drug-resistant infections and the patterns of antibiotic over-prescribing. In bringing together science and lived clinical experiences, I emphasize the immediate need for stewardship programs, public awareness campaigns, policy reform, and global surveillance. If coordinated action is not initiated, the post-antibiotic era is unlikely to be a prediction — instead, it may be already underway.

Index Terms: antibiotic resistance, global health, antimicrobial stewardship, emergency medicine, AMR policy, multidrug-resistant organisms

I. Introduction

Antibiotics transformed modern medicine and rendered previously fatal infections treatable. Misuse and overuse of antibiotics, however, have hastened the emergence of antibiotic-resistant bacteria to the point of endangering forty years of medical advances. The World Health Organization (WHO) ranked antibiotic resistance among the top ten worldwide public health dangers and estimated that drug-resistant infections may claim as many as 10 million lives annually by 2050 unless it is reined in.

This is not some theoretical future crisis — it is one already realized in hospitals worldwide. When I was working shifts in the emergency department at Hackensack Meridian, I encountered a patient who was unresponsive to first-line antibiotic treatment. As doctors escalated to broader-spectrum medication, the patient's condition deteriorated, revealing the boundaries of our therapeutic arsenal. This rendered the problem intensely personal. Antibiotic resistance is now no longer a matter of intellectual curiosity or a future worry; it is a present-day reality that healthcare practitioners encounter every day.

II. Mechanisms and Causes of Antibiotic Resistance

Antibiotic resistance is a natural process — bacteria are living organisms, and like all living organisms, they adapt in order to survive. Over time, bacteria can learn ways to protect themselves from antibiotics through either random genetic changes or trusting resistant mechanisms from other bacteria. Bacteria's defenses may consist of breaking down the drug, changing the structure of the target, and/or expelling the drug from the cell (Munita and Arias 1). The more we use antibiotics, the more opportunities bacteria have to learn and acquire these strategies for survival.

Unfortunately, human behavior is a significant factor influencing this process. One of the top drivers is overprescribing: ideally, antibiotics are used to treat diseases or infections caused by bacteria. However, antibiotics are often prescribed to treat illnesses like colds or flu, which are caused by viruses and are not treatable with antibiotics at all. Additionally, many patients stop taking the antibiotic because they feel better, which means the bacteria that survive have persisted long enough to modify and re-establish themselves. The CDC states that almost one-third (30 percent) of all outpatient antibiotic prescriptions in the U.S. are not necessary (CDC 5). In addition, the potential for evolution and resistance development in areas or regions of the world with less access to health care systems (which includes diagnostics), self-medicated antibiotics are the norm and are typically purchased without restriction.

This problem isn't just an issue with people. In agriculture, antibiotics are used on a larger scale for the prevention of sickness and promotion of growth in animals, particularly under conditions that raise challenges with population density or unsanitary conditions. The antibiotic use provides selective pressure on the development of resistant bacteria that live in animals, which incite possible transmission to humans through food, water, and the environment (Van Boeckel et al. 629).

Hospitals face a similar set of problems as resistant bacteria can easily spread in a medical setting where immunocompromised patients regularly undergo numerous interventions. Due to a lack of consistently adequate hygiene practices, overuse of invasive devices such as catheters, and unmotivated sanitation practices, dangerous strains of bacteria may thrive in hospitals and spread throughout a community. Drug resistant organisms, such as *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii* cause infections that are more difficult to treat, and the overall risk of complications and death is higher (Tacconelli et al. 418).

If antibiotics are not managed globally and at a local level - through smarter prescribing, stronger surveillance and commitment to the development of new treatments, the burden and transmission of antibiotic resistance will continue to grow. The implications are not just the disservice that individuals may experience, rather it could encumber the future of modern medicine.

III. Clinical Impact and Global Burden of Resistance

Antibiotic resistance is no longer theoretical or simply an isolated incident - it is now real in the clinic with global impact. Resistant infections cause patients more morbidity, generate longer lengths of stay, cost more to treat and have much higher mortality rates. According to the World Health Organization, in 2019, there were over 1.27 million attributable deaths from drug resistant bacterial infections - most of the burden in sub-Saharan Africa and South Asia (Murray et al. 55).

In the clinical encounter, patients who suffer from resistant infections often experience delayed treatment as confirmatory testing may not be readily available in under-resourced settings. This could lead to a greater chance of complications and poorer prognosis. Life threatening bloodstream, respiratory and urinary tract infections have been attributed to resistant infections from pathogens like *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and extended spectrum beta-lactamase (ESBL) producing *Escherichia coli*. It is often among immunocompromised patients, surgical wards and neonatal units that these infections pose the greatest risk (Tacconelli et al. 319).

Moreover, the economic burden of resistance is staggering. A report from the Review on Antimicrobial Resistance, while pointing out that there are substantial challenges, estimates that by the year 2050, antimicrobial resistance could potentially lead to a cumulative global gross domestic product (GDP) loss of \$100 trillion if effective interventions are not implemented (O'Neill, 2015). In the United States alone, it is estimated that drug-resistant infections cause approximately \$4.6 billion in direct health care costs per annum (CDC, 2019).

From a global health perspective, antibiotic resistance threatens many key achievements in public health including the safe provision of surgeries, cancer therapies, organ transplants, and maternal care. In many countries we are already losing antibiotics to common conditions such as pneumonia, sepsis and gonorrhea. The differences between wealthier resource-rich countries and resource-limited settings exacerbates containment of antimicrobials and antibiotics. Countries with fragile healthcare infrastructure face delayed access to effective drugs, the inconsistency in the reporting of resistance patterns, and limited investment in infection control and management.

IV. Solutions and Global Interventions

The increasing threat of antibiotic resistance requires a global and multifaceted response. The challenge can only be met with cooperation between health care systems, government, research institutions and the population. The size of the problem is staggering, however concerted efforts can have an effect on limiting the spread of resistant pathogens and extending the lifespan of current antibiotics.

Antibiotic stewardship programs are one of the key strategies. These programs encourage the appropriate use of antibiotics from a clinical standpoint by instructing clinical physicians to prescribe only when necessary and also the right agent, dose, and duration of therapy. Hospitals with stewardship programs report reduced rates of resistance and a reduction of overall healthcare costs (Baur et al. 2017).

Public education campaigns are equally important. Misunderstandings and ignorance are rampant. Little has changed in regards to public perception; many patients think antibiotics are effective for viral infections or they save their pertinent antibiotics. National and global campaigns, particularly WHO's "World Antimicrobial Awareness Week", can mitigate this and encourage appropriate behavior.

Several countries in the agricultural space have effectively instituted restrictions on antibiotic use with respect to growth promotion in livestock such as with the ban in the European Union in 2006 and more recently legislation implemented in India and China to limit nontherapeutic use. To modernize antibiotics in livestock globally, restrictions will decrease environmental reservoirs of resistance (Tang et al. 2017).

Concerted R&D investment is of critical importance. The antibiotic pipeline is nearly dry with minimal new drugs that target multidrug resistant Gram-negatives. Direct incentives from governments and private partnerships to pharmaceutical firms must include innovation incentives for alternatives such as for bacteriophage therapy, antimicrobial peptides, and rapid diagnostics.

On a systemic level, worldwide surveillance systems such as the World Health Organization (WHO) Global Antimicrobial Resistance Surveillance System (GLASS) are needed to track resistance trends around the world to impact policies. Access to real-time data would better equip policymakers for timely interventions and targeted containment especially given that most poor nations with limited resources would be isolated from globally shared insights.

Ultimately, the success of these interventions will depend on political action and most importantly international collaboration. Antibiotic resistance is a non-issue, and only if we, collectively, hold a sustained global effort will we prevent an eventual post-antibiotic era.

V. Conclusion and Call to Action

Antibiotic resistance is not an impending threat; it is a crisis upon us and exponentially worsening. Antibiotic resistance has made its mark in hospitals in New Jersey, pharmacies in Australia, and rural clinics throughout India. From all of these points, it is clear that life-saving antibiotics are losing the ability to save lives; normal treatments are becoming dangerously risky; and all health systems are becoming compromised. What used to be hailed as a marvel of modern medicine is now on the brink of perishing, unless we act immediately and all-spectrum, in a coordinated and collaborative response.

The determinants for resistance are multidimensional and complex - from clinical overuse to agricultural misuse, from low public awareness to many public health issues - they are solveable. We can do much better. Stewardship programs have continued to show their value; our global level surveillance is improving; and, when created broad enough and applied affordably, public education can positively influence behaviors in the way of cultural shifts, norm changes, and policy implementations. However, while there is research and evidence behind these programs, progress is still very fragile and variable.

As a student volunteer on the clinical frontlines, I have experienced the realities of resistance, but I have also been exposed to the resolute health care teams and their dedication to fight and improve it. These experiences have not only inspired my deep perception of my future in medicine, they have given me hope for a future with every infection has a cure and every patient has a shot at it.

Now it's up to us — future physicians, scientists, and global citizens — to safeguard the efficacy of antibiotics. Through research, innovation, and advocacy, we need to intervene and protect what was painstakingly made possible by previous generations: that medicine works.

Figure and Tables




Figure 1: Outpatient antibiotic prescriptions by category (CDC, 2019)




Figure 2: Estimated deaths from drug-resistant infections by region (Murray et al., 2022)

Author Bio

Ishal Chhipa is a pre-medical student at Seton Hall University, majoring in biology. Her academic journey reflects a deep commitment to global health, with clinical experience in emergency medicine and pediatric care in both the United States and India. She has led original research on respiratory disparities, published data-driven health studies, and developed educational initiatives for underserved communities. Passionate about bridging science and service, she aspires to become a physician who advances both patient care and public health through research, innovation, and advocacy.

References

Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. U.S. Department of Health and Human Services, 2019. www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Accessed 23 May 2025.

Munita, Jose M., and Cesar A. Arias. "Mechanisms of Antibiotic Resistance." *Microbiology Spectrum*, vol. 4, no. 2, Apr. 2016, pp. 1–37. doi:10.1128/microbiolspec.VMBF-0016-2015. Accessed 23 May 2025.

Tacconelli, Evelina, et al. "Discovery, Research, and Development of New Antibiotics: The WHO Priority List of Antibiotic-Resistant Bacteria and Tuberculosis." *The Lancet Infectious Diseases*, vol. 18, no. 3, 2018, pp. 318–327. doi:10.1016/S1473-3099(17)30753-3. Accessed 23 May 2025.

Van Boeckel, Thomas P., et al. "Global Trends in Antimicrobial Use in Food Animals." *Proceedings of the National Academy of Sciences*, vol. 112, no. 18, 2015, pp. 5649–5654. doi:10.1073/pnas.1503141112. Accessed 23 May 2025.

Murray, Christopher J. L., et al. "Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis." *The Lancet*, vol. 399, no. 10325, 2022, pp. 629–655. doi:10.1016/S0140-6736(21)02724-0. Accessed 23 May 2025.

O'Neill, Jim. *Tackling Drug-Resistant Infections Globally: Final Report and Recommendations*. Review on Antimicrobial Resistance, 2016. https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf. Accessed 23 May 2025.

Baur, Dominik, et al. "Effect of Antibiotic Stewardship on the Incidence of Infection and Colonization with Antibiotic-Resistant Bacteria and *Clostridium difficile* Infection: A Systematic Review and Meta-analysis." *The Lancet Infectious Diseases*, vol. 17, no. 9, 2017, pp. 990–1001. doi:10.1016/S1473-3099(17)30325-0. Accessed 23 May 2025.

Tang, Karen L., et al. "Restricting the Use of Antibiotics in Food-Producing Animals and Its Associations with Antibiotic Resistance in Food-Producing Animals and Human Beings: A Systematic Review and Meta-analysis." *The Lancet Planetary Health*, vol. 1, no. 8, 2017, pp. e316–e327. doi:10.1016/S2542-5196(17)30141-9. Accessed 23 May 2025.

